Interim analysis, phase 3, 864 patients with relapsed/refractory myeloma: talquetamab-daratumumab-pomalidomide and talquetamab-daratumumab both prolonged PFS vs daratumumab-pomalidomide-dexamethasone (HR 0.28 and 0.33). Serious adverse events 63.0%, 52.6%, 53.7%.
RCTn = 864 patients
Mina et al. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma